Wiendl H, Toyka K V, Rieckmann P, Gold R, Hartung H-P, Hohlfeld R
Department of Neurology and Clinical Research, Unit for MS and Neuroimmunology, University of Würzburg, Würzburg, Germany.
J Neurol. 2008 Oct;255(10):1449-63. doi: 10.1007/s00415-008-0061-1. Epub 2008 Oct 29.
This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature has been extracted for new evidence from randomized controlled trials, open treatment studies and reported expert opinion, both in original articles and reviews, and evaluates indications and safety issues based on published data. After data extraction from published full length publications and critically weighing the evidence and potential impact of the data, the review has been drafted and circulated within the National MS Societies and the European MS Platform to reach consensus within a very large group of European experts, combining evidence-based criteria and expert opinion where evidence is still incomplete. The review also outlines a few areas of controversy and delineates the need for future research.
本综述更新并扩展了早期与目前多发性硬化症(MS)基础及强化免疫调节治疗相关的共识报告。从随机对照试验、开放性治疗研究以及原始文章和综述中报道的专家意见中提取近期文献的新证据,并根据已发表的数据评估适应证和安全性问题。在从已发表的全文出版物中提取数据并严格权衡证据及数据的潜在影响后,起草了本综述并在各国MS协会和欧洲MS平台内进行传阅,以便在大量欧洲专家群体中达成共识,在证据仍不完整的情况下结合循证标准和专家意见。本综述还概述了一些争议领域,并阐述了未来研究的必要性。